アバスチン 化学特性,用途語,生産方法
解説
アバスチンは，結腸癌(けっちょうがん)・直腸癌(ちょくちょうがん)の治療薬「ベバシズマブ」の商品名。
小学館 デジタル大辞泉について 情報 | 凡例
効能
抗悪性腫瘍薬, 血管新生阻害薬, 抗VEGF抗体
Originator
Genentech (US)
来歴
Bevacizumab (Brand name: Avastin, developed by Genentech, Inc.) was first approved by the FDA on February 26, 2004, for the treatment of metastatic colorectal cancer. Subsequently, Avastin, alone or in combination with other anticancer drugs, was approved for the treatment of lung cancer, brain cancer (glioblastoma), kidney cancer, metastatic cervical cancer, platinum-resistant recurrent ovarian cancer, metastatic non-squamous non-small cell lung cancer, and hepatocellular carcinoma. On February 25, 2008, the FDA granted accelerated approval to Avastin in combination with paclitaxel chemotherapy for first-line treatment of advanced HER2-negative breast cancer. However, on November 18, 2011, the FDA withdrew Avastin's indication for breast cancer treatment. As of October 13, 2021, the FDA approved Merck's Keytruda (penzizumab) in combination with chemotherapy, whether or not it is combined with bevacizumab, as a treatment for patients with persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1).
brand name
Avastin
酵素阻害剤
This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.
target
Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents. Bevacizumab is a humanised recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.
アバスチン 上流と下流の製品情報
原材料
準備製品